Leading the Way in Life Science Technologies

GEN Exclusives

More »
Insight & Intelligence™

Related to FDA Details “Reasonable and Feasible” Trial Design for Orexigen’s Obesity Drug Contrave

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »